SCHEMBL4726083

SCHEMBL4726083

COc1cc(N)c2nc(C(C)C)c(C(C)CCCN)cc2c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.36
ESR1 P03372 2/20 0.33
PGR P06401 2/20 0.33
HTR1A P08908 2/20 0.33
PTGS1 P23219 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
OPRM1 P35372 2/20 0.33
SLC6A3 Q01959 2/20 0.33
KDM4E B2RXH2 2/20 0.33
DRD1 P21728 1/20 0.33
DRD3 P35462 1/20 0.33
NSD2 O96028 1/20 0.33
MAPT P10636 1/20 0.33
MAOA P21397 9/20 0.32
MAOB P27338 9/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
CYP1A2 P05177 2/20 0.32
ABCB11 O95342 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5083301 0.89 POLB (0.32)
SCHEMBL5086460 0.84 RAD52 (0.35) RAD52ESR1PGRHTR1APTGS1
SCHEMBL4727650 0.80 RAD52 (0.34) RAD52ESR1PGRHTR1APTGS1
SCHEMBL4780864 0.72 CYP1A2 (0.33) RAD52ESR1PGRHTR1APTGS1
SCHEMBL4726519 0.70 EHMT2 (0.35) PDE3AHTR2A
SCHEMBL5084092 0.70 EHMT1 (0.36) HTR2A
SCHEMBL4729403 0.67 SLC10A2 (0.38) RAD52KDM4ENSD2MAOACYP1A2
SCHEMBL4725459 0.65 EHMT2 (0.35) PDE3AHTR2A
SCHEMBL5080779 0.65 HSP90AA1 (0.53) ESR1PGRHTR1APTGS1SLC6A2
SCHEMBL5086202 0.64 EHMT2 (0.36) PDE3AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 RAD52 1960/4885ESR1 4791/4885PGR 4626/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN RAD52 3964/4885ESR1 4566/4885PGR 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.